Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM_net countries of the Eastern Mediterranean Region 2016-2020: Clinical and genetic studies.
Mariam AdamSami NahzatQutbuddin KakarMethaq AssadaBenoit WitkowskiAzza Tag Eldin ElshafieDuha AbuobaidaNaimullah SafiMunir Ahmed KhanMustafa NagiSayed Ali MustafaKhalilahmad KohestaniJamil MuhammadNimol KhimMohammed Al-HadiTarig Mohamed ElfakiMuhammad Naeem HabibAmna Khairy Abulkareem KhairyHamida HamidZain UddinYahya AmerAbdikarim Hussein HassanMousab Siddig ElhagAhmad Walid SediqiInamullah KakarRashad Abdul-GhaniJamal Ghilan Hefzullah AmranTarig Abdalla AbdallrahimMohammad Shoaib TamimAdel AljasariCharlotte RasmussenLina AzkoulMarian WarsamePublished in: Tropical medicine & international health : TM & IH (2023)
High efficacy of ASSP, AL and DP in the treatment of uncomplicated falciparum infection and of CQ and AL in the treatment of P. vivax was observed in the respective countries. The repeated detection of a relatively high rate of Pfk13 R622I mutation in Sudan underscores the need for close monitoring of the efficacy of recommended ACTs, parasite clearance rates and Pfk13 mutations in Sudan and beyond. Registration numbers of the trials: ACTRN12622000944730 and ACTRN12622000873729 for Afghanistan, ACTRN12620000426987 and ACTRN12617001025325 for Pakistan, ACTRN12618001224213 for Somalia, ACTRN12617000276358, ACTRN12622000930785 and ACTRN12618001800213 for Sudan and ACTRN12617000283370 for Yemen.